Rate of fracture in patients with glucocorticoid replacement therapy: a systematic review and meta-analysis

[1] Leelarathna L(2010)Co-morbidities, management and clinical outcome of auto-immune Addison’s disease Endocrine 38 113-117

[2] Breen L(2014)Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency J. Clin. Endocrinol. Metab. 99 E2715-E2721

[3] Powrie JK(2008)Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency Clin. Endocrinol. 69 697-704

[4] Thomas SM(2013)Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality J. Clin. Endocrinol. Metab. 98 1466-1475

[5] Guzder R(2009)Normal overall mortality rate in Addison’s disease, but young patients are at risk of premature death Eur. J. Endocrinol. 160 233-237

[6] McGowan B(2015)Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: a Swedish population-based national cohort study J. Clin. Endocrinol. Metab. 100 3520-3528

[7] Carroll PV(2019)Adrenal crisis N. Engl. J. Med 381 852-861

[8] Falhammar H(2017)Visceral fat and novel biomarkers of cardiovascular disease in patients with Addison’s disease: a case-control study J. Clin. Endocrinol. Metab. 102 4264-4272

[9] Frisén L(2005)Osteoporosis associated with excess glucocorticoids Endocrinol. Metab. Clin. North Am. 34 341-356

[10] Norrby C(2010)Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency Eur. J. Endocrinol. 163 15-20

[1] Leelarathna L(2010)Co-morbidities, management and clinical outcome of auto-immune Addison’s disease Endocrine 38 113-117

[2] Breen L(2014)Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency J. Clin. Endocrinol. Metab. 99 E2715-E2721

[3] Powrie JK(2008)Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency Clin. Endocrinol. 69 697-704

[4] Thomas SM(2013)Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality J. Clin. Endocrinol. Metab. 98 1466-1475

[5] Guzder R(2009)Normal overall mortality rate in Addison’s disease, but young patients are at risk of premature death Eur. J. Endocrinol. 160 233-237

[6] McGowan B(2015)Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: a Swedish population-based national cohort study J. Clin. Endocrinol. Metab. 100 3520-3528

[7] Carroll PV(2019)Adrenal crisis N. Engl. J. Med 381 852-861

[8] Falhammar H(2017)Visceral fat and novel biomarkers of cardiovascular disease in patients with Addison’s disease: a case-control study J. Clin. Endocrinol. Metab. 102 4264-4272

[9] Frisén L(2005)Osteoporosis associated with excess glucocorticoids Endocrinol. Metab. Clin. North Am. 34 341-356

[10] Norrby C(2010)Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency Eur. J. Endocrinol. 163 15-20